Gain Therapeutics Stock Cash Per Share
| GANX Stock | USD 1.75 0.11 5.91% |
Gain Therapeutics fundamentals help investors to digest information that contributes to Gain Therapeutics' financial success or failures. It also enables traders to predict the movement of Gain Stock. The fundamental analysis module provides a way to measure Gain Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gain Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 1.29 | 0.98 |
Gain | Cash Per Share |
Gain Therapeutics Company Cash Per Share Analysis
Gain Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Gain Therapeutics Cash Per Share | 2.04 X |
Most of Gain Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gain Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gain Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Gain Therapeutics is extremely important. It helps to project a fair market value of Gain Stock properly, considering its historical fundamentals such as Cash Per Share. Since Gain Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gain Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gain Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Gain Cash Per Share Historical Pattern
Today, most investors in Gain Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Gain Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Gain Therapeutics cash per share as a starting point in their analysis.
Gain Therapeutics Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
Gain Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, Gain Therapeutics has a Cash Per Share of 2.04 times. This is 53.1% lower than that of the Biotechnology sector and 52.89% lower than that of the Health Care industry. The cash per share for all United States stocks is 59.28% higher than that of the company.
Gain Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gain Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gain Therapeutics could also be used in its relative valuation, which is a method of valuing Gain Therapeutics by comparing valuation metrics of similar companies.Gain Therapeutics is currently under evaluation in cash per share category among its peers.
Gain Fundamentals
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 38.06 M | ||||
| Shares Outstanding | 26.53 M | ||||
| Shares Owned By Insiders | 5.09 % | ||||
| Shares Owned By Institutions | 7.96 % | ||||
| Number Of Shares Shorted | 718.74 K | ||||
| Price To Book | 5.54 X | ||||
| Price To Sales | 925.92 X | ||||
| Revenue | 55.18 K | ||||
| Gross Profit | (7.66 M) | ||||
| EBITDA | (22.17 M) | ||||
| Net Income | (22.27 M) | ||||
| Cash And Equivalents | 24.25 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 1.03 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 7.58 X | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (18.87 M) | ||||
| Short Ratio | 1.65 X | ||||
| Earnings Per Share | (1.07) X | ||||
| Target Price | 7.4 | ||||
| Number Of Employees | 29 | ||||
| Beta | 0.34 | ||||
| Market Capitalization | 49.34 M | ||||
| Total Asset | 18.61 M | ||||
| Retained Earnings | (60.78 M) | ||||
| Working Capital | 12.83 M | ||||
| Net Asset | 18.61 M |
About Gain Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gain Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gain Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gain Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.